US FDA Approved Amphastar Pharma’s Nasal Spray to Treat Opioid Overdose
The US Food and Drug Administration (FDA) has approved Amphastar Pharmaceuticals, Inc.’s New Drug Application (NDA) for naloxone hydrochloride nasal spray, 4 milligrams, to treat Opioid Overdose. Naloxone hydrochloride nasal spray 4mg is indicated for the immediate treatment of adult and pediatric patients suffering from respiratory and/or central nervous system depression as a result of […]
Continue Reading